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Abstract
Background: It has been hypothesized that radiotherapy (RT) techniques delivering radiations to larger volumes
(IMRT, VMAT) are potentially associated with a higher risk of second primary tumors. The aim of this study was to
analyse the impact of RT technique (3D-CRT vs IMRT/VMAT) on the incidence of second tumors in prostate cancer
(PCa) patients.
Methods: A retrospective study on 2526 previously irradiated PCa patients was performed. Patients were treated
with 3D-CRT (21.3%), IMRT (68.1%), or VMAT (10.6%). Second tumors incidence was analysed in 3 categories: pelvic,
pelvic and abdominal, and “any site”. The correlation with RT technique was analysed using log-rank test and Cox’s
proportional hazard method.
Results: With a median follow-up of 72 months (range: 9–185), 92 (3.6%) cases of second tumors were recorded
with 48 months (range: 9–152) median interval from RT. Actuarial 10-year second tumor free survival (STFS) was
87.3%. Ten-year STFS in patients treated with 3D-CRT and IMRT/VMAT was 85.8 and 84.5%, respectively (p: .627). A
significantly higher 10-year cumulative incidence of second tumors in the pelvis was registered in patients treated
with IMRT/VMAT compared to 3D-CRT (10.7% vs 6.0%; p: .033). The lower incidence of second pelvic cancers in
patients treated with 3D-CRT was confirmed at multivariable analysis (HR: 2.42, 95%CI: 1.07–5.47, p: .034).
Conclusions: The incidence of second pelvic tumors after RT of PCa showed a significant correlation with
treatment technique. Further analyses in larger series with prolonged follow-up are needed to confirm these results.
Keywords: Second malignancy, 3D-conformal radiotherapy, Intensity modulated radiotherapy, Volumetric
modulated arc therapy, Prostate neoplasms
Background
Prostate cancer (PCa) is the second most common can-
cer in men worldwide [1]. In the USA, data from the
Surveillance, Epidemiology and End Results database led
to a forecast of approximately 174,650 new diagnoses
and 31,620 deaths from PCa in 2019 [2].
Radiotherapy (RT) has been used in the treatment of
PCa for over 70 years. RT results have gradually improved
over time thanks to the technological evolution and to the
combination with adjuvant androgen deprivation therapy
(ADT). However, some studies suggested that patients
undergoing RT show a slightly higher incidence of second
primary tumors particularly in the pelvis [3–5], although
other authors attributed this increased risk to other factors
such as age and lifestyle [6].
In the late 1990s, 3-dimensional conformal RT (3D-
CRT) emerged as the optimal RT technique for this
tumor due to improved dose distribution compared to
conventional 2-dimensional RT. In fact, a significant re-
duction of acute and late toxicity was demonstrated [7,
8]. In the following decade, 3D-CRT was progressively
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replaced in this setting by modulated RT techniques
such as intensity-modulated RT (IMRT) first, and volu-
metric modulated arc therapy (VMAT) subsequently. In
fact, these techniques allow a higher dose conformity
due to the steeper dose gradients around the target vol-
ume, reduced irradiation of organs at risk (OAR), and
therefore the delivery of higher RT doses to the tumor
[9–13]. A meta-analysis showed that IMRT, compared
to 3D-CRT, can achieve lower G2–4 rectal toxicity rates
and improve biochemical relapse-free survival [14].
However, it is well known that modulated RT tech-
niques lead to low-level doses in larger body volumes
compared to 3D-CRT. Theoretically, this characteristic
could increase the risk of RT-induced carcinogenesis
and then of second tumors. The theoretically increased
risk of IMRT/VMAT induced second tumors in PCa
patients has been largely discussed in literature. Several
studies addressed this topic mainly in planning and
dosimetric analyses [15–18]. However, comparisons be-
tween 3D-CRT and modulated RT techniques in terms
of second tumors incidence based on real clinical data
are still lacking.
Therefore, the aim of this retrospective analysis was to
evaluate the impact of RT technique (3D-CRT vs IMRT/
VMAT) on the incidence of second primary tumors in
PCa patients. Moreover, also the impact of ADT and ir-
radiated volumes in terms of delivery or not of prophy-
lactic nodal irradiation (PNI), was investigated.
Methods
End points and study design
The primary end point of this study was the correlation of
RT technique with second primary cancers incidence in
PCa. The secondary objectives of the analysis were the
correlation of ADT and PNI on the same outcome. The
study design was a monocentric retrospective analysis on
all PCa patients previously treated with external beam RT
(EBRT) included in our institutional PCa database.
Inclusion criteria
Inclusion criteria were as follows: 1) histologically con-
firmed prostatic adenocarcinoma; 2) curative aim of RT;
3) age > 18 years. Exclusion criteria were: 1) patients with
distant metastases; 2) palliative aim of RT; 3) previous
chemotherapy or RT on any site of the body; 4) some
diseases potentially affecting tolerance to radiation ther-
apy and potentially associated to a higher risk of cancer:
ulcerative colitis, Crohn’s disease, familial adenomatous
polyposis, and bladder papilloma; 5) patients with malig-
nancies diagnosed prior to PCa diagnosis; 6) patients
with malignancies diagnosed during PCa staging and
planning.
Radiotherapy
All patients underwent computed tomography (CT) simu-
lation in supine position using a personalized
immobilization system. In some patients, Positron Emis-
sion Tomography (18F-choline or 11C-choline or 68-Ga-
PSMA) - CT simulation and/or CT-simulation image fu-
sion with MRI scans were performed. The Clinical Target
Volumes (CTV) were defined based on risk categories to
include only the prostate (or prostatic bed) +/− seminal
vesicles or also pelvic lymph nodes. An isotropic margin
ranging between 5 and 10mm was added to the CTV to
define the Planning Target Volumes. The photon beam
energy was 10–15 MV and 6 MV in patients treated with
3D-CRT and IMRT/VMAT, respectively. As previously
described, daily set-up verification was performed using
an Electronic Portal Imaging Device in most patients [19].
Only in a small minority of patients treated after 2016,
set-up and organ motion evaluation was performed using
a cone-beam CT. Dose specification and prescription were
performed based on the International Commission of Ra-
diation Unit reports 62 and 83 for 3D-CRT and IMRT/
VMAT techniques, respectively [20, 21]. ADT was pre-
scribed according to risk categories.
Follow-up
Patients were monitored weekly during RT. For a more
precise estimate of acute toxicity, patients were evaluated at
one month after the end of RT. Subsequently the patients
were followed biannually for the first 5 years and annually
thereafter. At each visit total PSA, blood count and urine
test were requested. During each visit, the patients under-
went rectal exploration and an interview on any symptoms
that appeared in previous months. In the case of at least 2
episodes of rectal bleeding, the patients were referred to
proctoscopy and, in cases of persistent bleeding, to total
colonoscopy. In the case of microscopic or macroscopic
hematuria, in the absence of clear signs of inflammation,
patients were asked to undergo cystoscopy. In the case of
recurrent bleeding, a renal and ureteral ultrasound was pre-
scribed. Overall, 193 patients were lost at follow-up.
Statistical analysis
The IBM SPSS Version 22.0 software package was used for
statistical computation (IBM Corp, Armonk, NY, USA).
Survival estimates were calculated by the Kaplan-Meier
product-limit method and compared with the log-rank test.
Multivariate analysis was performed using a Cox regression
model [22]. Also a Fine and Gray competing risk survival
regression analysis was performed in R (version 3.5.2) using
the library package “survival” and “cmprsk” to consider
deaths from other causes as competing events. A p < 0.05
value was considered statistically significant. The impact of
RT technique (3D-CRT vs IMRT/VMAT), ADT (yes or
not), and PNI (yes or not) on the incidence of second
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primary tumors was estimated. Second tumors incidence
was evaluated not only as “any second tumor” detected dur-
ing the follow-up but also considering other 2 groups: i)
second tumors in the pelvis and ii) second tumors in the
abdomen or pelvis. In cases of doubtful interpretation of
the information contained in the database for the purposes
of this stratification, the diagnostic images of the second
tumor were analysed.
Ethical issues
The local institutional review board approved this ana-
lysis (311/2019/Oss/AOUBo, ICAROS-1 study). Only
patients who had provided a written informed consent
to the scientific use of their data were included.
Results
Patients characteristics
We included in the analysis 2526 PCa patients who met
the inclusion criteria and received EBRT between 2002
and 2018. Median follow-up was 72months (range: 9–
185 months) and median age was 71 years (range: 43–93
years). The RT settings were definitive (54.2%), adjuvant
(32.8%), or salvage treatment (13.0%). Patients were
treated with 3D-CRT technique (21.3%), IMRT (68.1%),
or VMAT (10.6%). Total 3D-CRT median delivered dose
was 70 Gy (median dose/fraction: 2.5 Gy) and the total
IMRT/VMAT median dose was 67.5 Gy (median dose/
fraction: 2.6 Gy). PNI and ADT were prescribed to 1294
(51.2%) and 1689 (66.9%) patients, respectively. Patients
treated with 3D-CRT and IMRT/VMAT received PNI in
39.4 and 54.4% of cases, respectively.
Incidence of second tumors
Ninety-two (3.6%) cases of second tumors were re-
corded. Median interval between RT and second tumor
was 48months (range: 9–152 months) and median age
was 70 years (range: 45–83 years) at diagnosis of the sec-
ond cancer. Moreover, there were 31 (1.2%), 26 (1.0%),
and 35 (1.4%) cases of second primary cancers detected
in the pelvis, abdomen, and other sites, respectively.
Considering the group of younger patients (≤ 66 years:
first quartile), we recorded 25 s tumors out of 688 cases.
This information on second tumors was collected from
patient chart-records. Table 1 shows the number and










No 515 (95.7) 1660 (96.6) 259 (96.3) 2434 (96.4)
Pelvis
Bladder 8 (1.5) 19 (1.1) 4 (1.5) 31 (1.2)
Rectum 0 (0.0) 4 (0.2) 1 (0.4) 5 (0.2)
Sigma 0 (0.0) 2 (0.1) 0 (0.0) 2 (0.1)
Abdomen
Colon 0 (0.0) 4 (0.2) 1 (0.4) 5 (0.2)
Stomach 0 (0.0) 4 (0.2) 1 (0.4) 5 (0.2)
Kidney 2 (0.4) 1 (0.1) 0 (0.0) 3 (0.1)
Pancreas 2 (0.4) 0 (0.0) 0 (0.0) 2 (0.1)
Small bowel (duodenal) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.0)
Small bowel (ileum) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.0)
Other sites
Lung 4 (0.7) 6 (0.3) 2 (0.7) 12 (0.5)
Melanoma 1 (0.2) 7 (0.4) 0 (0.0) 8 (0.3)
Skin 0 (0.0) 6 (0.3) 0 (0.0) 6 (0.2)
Head and neck 2 (0.4) 2 (0.1) 0 (0.0) 4 (0.2)
Brain 0 (0.0) 3 (0.2) 0 (0.0) 3 (0.1)
Lymphoma 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.0)
Leukaemia 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.0)
Oesophagus 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.0)
Lip 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.0)
Legend: 3D-CRT three-dimensional conformal radiotherapy; IMRT Intensity modulated radiotherapy, VMAT volumetric modulated radiotherapy
BUWENGE et al. BMC Cancer           (2020) 20:90 Page 3 of 8
percentages of detected second tumors. The 10-year
actuarial cumulative incidence of second tumors was
14.4%.
Impact of treatment characteristics on second tumors
incidence
For the entire cohort, the calculated 10-year second tumor-
free survival (STFS) in patients treated with 3D-CRT and
IMRT/VMAT was 85.8 and 84.5%, respectively (p: .627).
At univariate analysis, 10-year STFS in patients treated
with or without PNI was 84.9 and 88.1%, respectively (p:
.770). Ten-year STFS in patients receiving or not ADT
was 83.8 and 92.8%, respectively (p: .999). A significantly
higher 10-year cumulative incidence of second tumors
in the pelvis was registered in patients treated with
IMRT/VMAT compared to 3D-CRT (10.7% vs 6.0%; p:
.033). Moreover, PNI showed a trend (p: 0.1) for in-
creased 10-year incidence of second tumors in both pel-
vis (9.4% vs 5.6%, p: .092) and pelvis-abdomen (10.9% vs
7.4%, p: .064) (Table 2, Fig. 1).
Stratifying patients in 4 groups according to used RT
technique and irradiated volumes, a statistically signifi-
cant difference was recorded in terms of STFS in the
pelvis (p: .044). The 10-year STFS were as follows: 3D-
CRT without PNI: 96.6%; 3D-CRT with PNI: 93.7%;
IMRT/VMAT without PNI: 89.9%; and IMRT/VMAT
with PNI: 87.6% (Table 2, Fig. 2).
On multivariate analysis (Table 3), the lower incidence
of second pelvic cancers in patients treated with 3D-
CRT was confirmed (hazard ratio [HR]: 2.42, 95%CI:
1.07–5.47, p: .034). Furthermore, the incidence of second
pelvis-abdomen cancers were found to have a trend in
case of PNI delivery (HR: 1.63, 95%CI: 0.95–2.79, p:
.067). Moreover, in a separate multivariate analysis
where RT techniques and irradiated volumes were com-
bined, patients treated with IMRT/VMAT plus PNI were
found to have a significantly increased risk of second
pelvic cancers (HR: 3.24, 95%CI: 1.09–9.65, p: .035) and
second pelvis-abdomen cancers (HR: 2.61, 95%CI: 1.06–
6.41, p: .037). The Fine and Gray regression model ana-
lysis confirmed a trend of influence of IMRT/VMAT on
the incidence of pelvic tumors (p: 0.058). Furthermore,
considering the combination of radiotherapy technique
and irradiated volumes, the same model confirmed the
significant impact of IMRT/VMAT plus PNI on pelvic
(p: 0.033) and pelvic or abdominal (p: 0.034) second tu-
mors, using 3D-CRT without PNI as a reference.
Discussion
We performed an analysis on the incidence of second can-
cers in PCa patients treated with EBRT to evaluate the im-
pact of RT technique, irradiated volumes, and ADT. The
analysis showed a significant correlation between 10-year
incidence of second tumors located in the pelvis and RT
technique [3D-CRT vs IMRT (6.0% vs 10.7%, p: .033)],
while PNI showed a trend for increased 10-year incidence
of second tumors in both pelvis (9.4% vs 5.6%, p: .092) and
pelvis-abdomen (10.9% vs 7.4%, p: .064).
Our study has several limitations which simply make it
a hypothesis generating analysis. First, the median
follow-up is relatively short (72 months). In fact, in a co-
hort of Hodgkin’s Lymphoma patients treated with RT,
the median latency time to second tumor was 7.5 years
[23]. We cannot completely exclude that with a longer
follow-up, the recorded differences could lose their stat-
istical significance. Furthermore, not having defined a
minimum follow-up duration as an inclusion criterion, it
is possible that some of the second malignancies
Table 2 Univariate analysis (10-year Second Tumor-Free Survival)
Variables No. of patients
(%)
all sites pelvis pelvis/abdomen
STFS p STFS p STFS p
Radiotherapy technique 3D-CRT 538 (21.3) 85.8 .627 94.0 .033 92.2 .125
IMRT/VMAT 1988 (78.7) 84.5 89.3 87.5
Prophylactic nodal irradiation no 1232 (48.8) 88.1 .770 94.4 .092 92.6 .064
yes 1294 (51.2) 84.9 90.6 89.1
Androgen deprivation therapy no 837 (33.1) 92.8 .999 93.1 .546 92.0 .345
yes 1689 (66.9) 83.8 91.9 89.9
Age, years ≤ 66 688 (27.2) 85.3 .352 90.5 .981 89.6 .374
> 66 1838 (72.8) 86.0 93.5 91.4
Combination of radiotherapy
technique and irradiated volumes
3D-CRT without PNI 326 (12.9) 91.0 .887 96.6 .044 95.3 .140
IMRT/VMAT without PNI 906 (35.9) 78.9 89.9 87.8
3D-CRT with PNI 212 (8.4) 85.6 93.7 91.1
IMRT/VMAT with PNI 1082 (42.8) 86.6 87.6 86.3
Legend: 3D-CRT three-dimensional conformal radiotherapy, IMRT Intensity modulated radiotherapy, PNI prophylactic nodal irradiation, STFS second tumor free
survival, VMAT volumetric modulated radiotherapy
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Fig. 1 actuarial cumulative risk of pelvic second primary tumors after radiotherapy (3D- conformal therapy vs modulated techniques; p: .033)
Fig. 2 actuarial cumulative risk of pelvic second primary tumors after radiotherapy (3D-conformal radiotherapy without prophylactic nodal
irradiation versus 3D-conformal radiotherapy with prophylactic nodal irradiation versus modulated radiotherapy techniques without prophylactic
nodal irradiation versus modulated radiotherapy techniques with prophylactic nodal irradiation; p: .044)
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diagnosed during the follow-up had arisen before RT.
This aspect may have influenced the results of the ana-
lysis. Moreover, the sample size (2526 patients) can be
considered relatively small. In fact, other studies in this
field [3, 6, 24], two of which were registry studies [3, 24],
included 9538–619,479 patients. Even this small sample
size could potentially have affected the results of the ana-
lysis. Furthermore, although image guided RT could add a
non-negligible risk for second tumors when daily set-up
verification with high-resolution modality is performed
[13], we did not consider this issue in our analysis. How-
ever, it should be noted that no extra dose was delivered
for set-up verification in most patients. Furthermore, only
a small minority of patients treated in the last 2 years had
their treatment position and organ motion checked using
a daily cone-beam CT. In addition, the evaluation of other
potential factors correlated with second tumors are lacking
in our analysis. For example, the first 2 primary tumors re-
corded in this study were bladder and lung cancers and
both are smoking-related malignancies. Therefore, it
would have been interesting to evaluate the impact of RT
techniques also considering the smoking habits of individ-
ual patients. Unfortunately, even in this case, this data is
only available in a minority of patients and therefore could
not be analysed. Moreover, it should be noted that until
2009 (when all patients of the 3D-CRT group were
treated), the cranial margin for pelvic nodes delineation
was at the level of the anterior margin of the S1 vertebra.
From 2009 (when all patients were treated with modulated
techniques), this margin was moved slightly cranially, at
the level of the S1-L5 interspace. Therefore, we cannot rule
out that most patients undergoing modulated techniques
received a slightly more extensive irradiation in the cranial
direction and that this may have influenced the results of
our analysis.
Finally, patients with short observation time were not ex-
cluded in order to consider a reasonable latency time be-
tween RT and onset of the second tumor. For example, in a
previous study, the analysis of second solid cancers was
based only on 5-year survivors and analysis of leukemia were
based only on 2-year survivors [25]. However, given the un-
certainty about the latency times of second tumors occur-
rence, we decided to use a conservative criterion and
therefore to include all primitive tumors diagnosed after RT.
In the past, even if the results are somehow contradictory
[26] and the incidence of second tumors could also be at-
tributed to age and lifestyles [6], several analyses showed an
increased risk for second tumors after EBRT of PCa [3–5,
24]. Probably these data should be considered with caution.
In fact, in previously cited studies [3–5, 24], the incidence
of second tumors was evaluated by comparing PCa patients
who underwent RT with subjects receiving other treat-
ments, mainly represented by radical prostatectomy (RP).
In this regard, it should be noted that in different risk cat-
egories, RT and RP are considered as alternative thera-
peutic options. However, in daily clinical practice, the
choice between the two treatments is often based on pa-
tient’s comorbidities. In particular, RT is preferred to RP in
case of contraindications to surgery. These contraindica-
tions (COPD, cardiovascular diseases, metabolic syndrome)
are more frequent in smoking patients and these subjects
are obviously more prone to smoke-related malignancies
such as bladder or lung tumors.
Some studies evaluated also the impact of RT technique
on the incidence of second tumors. In particular, three
meta-analyses uniformly recorded a higher incidence of
second rectal tumors after EBRT but not after brachyther-
apy [4, 5, 26]. In another study no differences were ob-
served in terms of overall incidence of second tumors
between 2D-conventional and 3D-CRT but only an advan-
tage in patients undergoing 3D-CRT in terms of second
rectal tumors. In the same analysis, no significant differ-
ences were observed based on beams photons energy (>
10 MV versus ≤10 MV) but a reduction in colon and leu-
kaemia tumors in patients undergoing brachytherapy
compared to those treated with external beams [25].
However, to the best of our knowledge, our study is
the first analysis comparing 3D-CRT vs IMRT/VMAT
Table 3 Multivariate analysis on second tumor free survival
Variable value pelvic Pelvic-abdominal
HR 95%CI p HR 95%CI p
Radiotherapy technique 3D-CRT Ref
IMRT/VMAT 2.42 1.07–5.47 .034
Prophylactic nodal irradiation No Ref
Yes 1.63 0.95–2.79 .067
Combination of radiotherapy
technique and irradiated volumes
3D-CRT without PNI Ref Ref
IMRT/VMAT without PNI 1.70 0.53–5.51 .375 1.66 0.64–4.29 .294
3D-CRT with PNI 1.10 0.27–4.46 .892 1.73 0.61–4.92 .303
IMRT/VMAT with PNI 3.24 1.09–9.65 .035 2.61 1.06–6.41 .037
Legend: 3D-CRT three-dimensional conformal radiotherapy, IMRT Intensity modulated radiotherapy, PNI prophylactic nodal irradiation, VMAT volumetric
modulated radiotherapy
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techniques and evaluating also the impact of PNI and
ADT. Furthermore, we considered the incidence of sec-
ond tumors in different body regions (pelvis, pelvis or
abdomen, and all together). The results of our analysis
based on clinical data are in agreement with several
dosimetric and planning studies predicting a higher inci-
dence of bladder and/or rectal second cancers in pa-
tients treated with modulated techniques [15–18].
More generally, our study showed a 14.4% 10-year in-
cidence of second tumors. Considering the favourable
prognosis related to PCa (10-year OS: 87.3% in our
series), this result should stimulate attention during the
follow-up of patients not only to eventual PCa relapse
but also to the risk of second tumors. In particular,
haematuria or rectal bleeding should not be automatic-
ally considered as late RT induced toxicity but should
also lead to further investigations on the possibility of
bladder or rectal cancer, respectively.
Given the increased risk of radiation induced second
tumors in PCa patients receiving RT, this possibility
should be discussed with patients before treatment [3].
Based on our analysis, not showing a significant increase
in the overall incidence of second cancers, further expla-
nations about the potential additional risk from modu-
lated RT techniques seem not required.
However, further analysis with prolonged follow-up,
possibly on larger patients’ population and considering
other risk factors such as smoking habits, should be per-
formed to confirm our findings.
Conclusions
The results of our study suggest a correlation between the
use of modulated techniques and the incidence of second
pelvic tumors in RT of PCa. Furthermore, the combin-
ation of modulated techniques and PNI seems to increase
the incidence of second abdominal-pelvic tumors. These
results appear relevant given that: i) they justify the plan-
ning of further studies on this topic; ii) if confirmed by
these future analyses, they would represent the first “clin-
ical” confirmation of the hypothetical impact of modu-
lated techniques on the incidence of second tumors; iii)
these results suggest particular attention, in the follow up
of patients treated with modulated techniques, to the early
diagnosis of second pelvic tumors and, in case of PNI, also
of second abdominal tumors.
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